---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-22-000586"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2022-09-20T23:59:59+00:00"
generated_at: "2026-06-23T08:31:57.721589+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Regen BioPharma files patent on RNA/DNA dual checkpoint-gene silencing immunotherapy

## Summary
- Filed provisional patent 'Dual Checkpoint Inhibitor Aptamer Based Therapeutics' targeting NR2F6 and Survivin gene silencing combined with PD-1 checkpoint inhibition.
- Company claims it is the first combination of immunotherapy and gene silencing in a single drug.
- Technology uses aptamers (short DNA/RNA) to deliver gene-silencing sequences while inhibiting traditional immune checkpoints like PD-1.
- CEO David Koos believes platform will yield numerous potent therapeutic candidates.

## SEC filing metadata
- accession: 0001607062-22-000586
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2022-09-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000586/0001607062-22-000586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000586/rgbp091922form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-22-000586
- JSON: https://secwatch.observer/filing/0001607062-22-000586.json
- Plain text: https://secwatch.observer/filing/0001607062-22-000586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.